News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Ethical approval for LCT’s NTCELL® Phase I trial

Living Cell Technologies Limited
Company Announcement

Ethical approval for LCT’s NTCELL® Phase I trial

16 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has received ethical approval from the New Zealand Ministry of Health’s Health and Disability Ethics Committee to proceed with Phase I clinical trials of NTCELL® for Parkinson’s disease.
"We are extremely pleased to have received ethical approval in such an efficient timeframe," says Dr Andrea Grant, Chief Executive of LCT. "It means that LCT is still on track to commence NTCELL’s first in-human trials in Q1 2013.
LCT received regulatory authorisation from Medsafe to proceed with trials in October.

– Ends –

For further information:

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Werewolf Film: It Follows - Panic In Detroit

Philip Matthews: When you heard last month that Wes Craven had died and you wanted to pay homage, you could have sat down with any one of five of his films that helped reinvent American horror at least three times over three decades... Or you could just have watched one of the greatest recent horror films that would probably not exist without Craven. More>>


Werewolf Music: Searching For The White Wail - On Art Pepper, etc

If the word ‘hipster’ means anything – which it arguably doesn’t – it seems to be more of an impulse than a condition. One always headed for the margins, and away from the white-bred, white-bread mainstream... More>>


Scoop Review Of Books: Leonardo da Vinci - The Graphic Work

The breadth of da Vinci’s work is incredible: from animals to weaponry, architecture to fabric, maps to botany. The works have been divided into themes such as Proportion Drawings, Anatomical Drawings and Drawings of Maps and Plans. Each section begins with a short essay. More>>

Scoop Review Of Books: James Hector: Explorer, Scientist, Leader

Publication of this comprehensive 274-page account of the life and work of James Hector by the Geoscience Society of New Zealand marks the 150th anniversary of James Hector’s appointment as New Zealand’s first government scientist. More>>

On Shoestrings And Phones: Rossellini And Contemporary Film

Howard Davis: Roberto Rossellini's Neo-Realist Rome, Open City provides some fascinating technical parallels to Tangerine, an equally revolutionary Independent movie made exactly seventy years later. More>>

Art Review: Fiona Pardington's A Beautiful Hesitation

An aroma of death and decay perfumes this extraordinary survey of Fiona Pardington's work with faint forensic scents of camphor and formaldehyde. Eight large-format still-lifes dominate the main room, while other works reveal progressive developments in style and subject-matter. More>>

Get More From Scoop



Search Scoop  
Powered by Vodafone
NZ independent news